BR122019016210B8 - composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo - Google Patents

composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo

Info

Publication number
BR122019016210B8
BR122019016210B8 BR122019016210A BR122019016210A BR122019016210B8 BR 122019016210 B8 BR122019016210 B8 BR 122019016210B8 BR 122019016210 A BR122019016210 A BR 122019016210A BR 122019016210 A BR122019016210 A BR 122019016210A BR 122019016210 B8 BR122019016210 B8 BR 122019016210B8
Authority
BR
Brazil
Prior art keywords
compound
mediated
amino acid
receptor activity
chain
Prior art date
Application number
BR122019016210A
Other languages
English (en)
Other versions
BR122019016210B1 (pt
Inventor
Romagnoli Barbara
Ludin Christian
Obrecht Daniel
Gombert Frank
Henze Heiko
Wim Vrijbloed Jan
Anthony Robinson John
Zumbrunn Jürg
Moehle Kerstin
Mukherjee Reshmi
Lociuro Sergio
J Demarco Steven
Original Assignee
Polyphor Ag
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag, Univ Zuerich filed Critical Polyphor Ag
Publication of BR122019016210B1 publication Critical patent/BR122019016210B1/pt
Publication of BR122019016210B8 publication Critical patent/BR122019016210B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

(i) sendo que z é uma cadeia fixada-a-template de 12, 14 ou 18 radicais de aminoácido a que, dependendo de suas posições na cadeia (contadas partindo do aminoácido n-terminal), são gly, nmegly, pro ou pip, ou de determinados tipos que, como os símbolos restantes na fórmula acima, são definidos na descrição e nas reivindicações, e sais dos mesmos, apresentam propriedades antagonisadoras de cxcr4 e podem ser usados para prevenir infecções com hiv em indivíduos saudáveis ou para desacelerar e interromper progressao viral em pacientes infectados; ou onde câncer é mediado ou resultante de atividade de receptor cxcr4; ou onde doenças imunológicas são mediadas ou resultantes de atividade de receptor cxcr4; ou para tratar imunossupressão; ou durante coletas de aferese de células-tronco de sangue periférico. estes peptidomiméticos de beta-hairpin podem ser fabricados por meio de um processo que é baseado numa estratégia sintética mista de fase sólida e solução.
BR122019016210A 2003-05-02 2004-04-29 composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo BR122019016210B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2003/004640 2003-05-02
PCT/EP2003/004640 WO2004096839A1 (en) 2003-05-02 2003-05-02 Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
PCT/EP2004/004535 WO2004096840A1 (en) 2003-05-02 2004-04-29 Template- fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
BRPI0409928A BRPI0409928B8 (pt) 2003-05-02 2004-04-29 composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo
PI0409928-1 2004-04-29

Publications (2)

Publication Number Publication Date
BR122019016210B1 BR122019016210B1 (pt) 2020-09-08
BR122019016210B8 true BR122019016210B8 (pt) 2021-07-27

Family

ID=33395700

Family Applications (3)

Application Number Title Priority Date Filing Date
BRPI0409928A BRPI0409928B8 (pt) 2003-05-02 2004-04-29 composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo
BR122019016210A BR122019016210B8 (pt) 2003-05-02 2004-04-29 composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo
BR122019016211A BR122019016211B8 (pt) 2003-05-02 2004-04-29 composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0409928A BRPI0409928B8 (pt) 2003-05-02 2004-04-29 composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019016211A BR122019016211B8 (pt) 2003-05-02 2004-04-29 composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo

Country Status (17)

Country Link
US (3) US7786078B2 (pt)
EP (3) EP1622931B1 (pt)
JP (3) JP4846564B2 (pt)
KR (5) KR20130059463A (pt)
CN (1) CN1802385B (pt)
AU (2) AU2003232253A1 (pt)
BR (3) BRPI0409928B8 (pt)
CA (3) CA2524253C (pt)
EA (1) EA010163B1 (pt)
ES (3) ES2550856T3 (pt)
HK (1) HK1094210A1 (pt)
IL (3) IL171530A (pt)
MX (1) MXPA05011550A (pt)
NO (2) NO333793B1 (pt)
NZ (1) NZ543806A (pt)
WO (2) WO2004096839A1 (pt)
ZA (1) ZA200508863B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105111280B (zh) * 2005-02-17 2020-01-24 波利弗尔有限公司 具有蛋白酶抑制活性的模板固定的β-发夹肽模拟物
EP1856140B1 (en) * 2005-02-17 2013-12-25 Polyphor Ltd. Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity
WO2006117011A1 (en) * 2005-05-02 2006-11-09 Polyphor Ltd. Dye conjugates of template-fixed peptidomimetics
ES2427989T3 (es) 2005-10-28 2013-11-05 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
PL1961744T3 (pl) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie
WO2007079597A1 (en) * 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
AU2007345497B2 (en) * 2007-01-29 2013-01-17 Polyphor Ltd. Template-fixed peptidomimetics
PL2132221T3 (pl) 2007-02-28 2011-04-29 Polyphor Ltd Przyłączone do matrycy peptydomimetyki
WO2009074807A2 (en) 2007-12-12 2009-06-18 Imperial Innovations Limited Methods
US20110230426A1 (en) * 2008-08-08 2011-09-22 Polyphor Ag Template-fixed peptidomimetics
US8883720B2 (en) 2008-11-26 2014-11-11 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity
WO2010127704A1 (en) * 2009-05-07 2010-11-11 Polyphor Ag Beta-hairpin peptidomimetics having cxcr4 antagonizing activity
SG195055A1 (en) 2011-06-07 2013-12-30 Polyphor Ag Beta - hairpin peptidomimetics as cxc4 antagonists
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
WO2013050346A1 (en) 2011-10-07 2013-04-11 Polyphor Ag Template -fixed peptidomimetics as inhibitors of fpr1
ES2647076T3 (es) * 2012-06-06 2017-12-19 Polyphor Ag Peptidomiméticos de horquilla beta
AU2013301576B2 (en) * 2012-08-08 2017-10-19 Polyphor Ag Combinations with a backbone-cyclized peptide
US10544527B2 (en) * 2015-03-24 2020-01-28 Toray Industries, Inc. Fabric and clothing having flame retardancy and high visibility
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
EP3630153A2 (en) * 2017-05-22 2020-04-08 National Hellenic Research Foundation Macrocyclic modulators of disease associated protein misfolding and aggregation
WO2023227771A1 (en) 2022-05-27 2023-11-30 Fundación Privada Instituto De Salud Global Barcelona Cyclic peptides with antibacterial activity against multidrug resistant (mdr) pathogens

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177114T1 (de) 1993-10-14 1999-03-15 Seikagaku Kogyo Co Ltd Polypeptide und daraus hergestellte, gegen hiv wirksame substanzen
EP1214336A1 (en) * 1999-08-30 2002-06-19 Universität Zürich Synthesis of template-fixed beta-hairpin loop mimetics
US7253146B2 (en) * 2001-02-23 2007-08-07 Polyphor Ltd Template-fixed peptidomimetics with antimicrobial activity
CN101157924A (zh) * 2001-12-11 2008-04-09 人体基因组科学有限公司 嗜中性白细胞因子α
AU2002342618C1 (en) * 2002-08-20 2008-10-30 Polyphor Ltd. Template-fixed peptidomimetics with antibacterial activity
ATE393774T1 (de) * 2002-10-02 2008-05-15 Polyphor Ltd Matrizenfixierte peptidomimetika mit antimikrobieller wirkung

Also Published As

Publication number Publication date
NZ543806A (en) 2008-03-28
EP2540735A3 (en) 2013-02-27
BRPI0409928A (pt) 2006-04-25
EA200501550A1 (ru) 2006-06-30
IL227933A0 (en) 2013-09-30
EP1622931B1 (en) 2015-07-15
EP2540735B1 (en) 2015-07-22
JP2013227317A (ja) 2013-11-07
CA2847490C (en) 2015-11-17
KR101330239B1 (ko) 2013-11-15
CA2847490A1 (en) 2004-11-11
BR122019016210B1 (pt) 2020-09-08
IL171530A (en) 2013-08-29
CA2524253A1 (en) 2004-11-11
MXPA05011550A (es) 2006-07-06
US7786078B2 (en) 2010-08-31
KR20060034217A (ko) 2006-04-21
KR20110089173A (ko) 2011-08-04
EP2540736A3 (en) 2013-02-27
NO20055585L (no) 2005-11-25
EP2540735A2 (en) 2013-01-02
ES2563094T3 (es) 2016-03-10
WO2004096840A1 (en) 2004-11-11
NO333793B1 (no) 2013-09-16
CN1802385B (zh) 2011-11-09
US20070078079A1 (en) 2007-04-05
EA010163B1 (ru) 2008-06-30
IL227932A0 (en) 2013-09-30
ES2550856T3 (es) 2015-11-12
ZA200508863B (en) 2007-03-28
BR122019016211B8 (pt) 2021-07-27
CA2524253C (en) 2016-03-29
JP2011140496A (ja) 2011-07-21
KR20110089174A (ko) 2011-08-04
ES2550241T3 (es) 2015-11-05
EP2540736B1 (en) 2015-11-18
US20150087577A1 (en) 2015-03-26
KR20130059463A (ko) 2013-06-05
AU2004234062A1 (en) 2004-11-11
HK1094210A1 (en) 2007-03-23
BRPI0409928B8 (pt) 2021-05-25
US20110245155A1 (en) 2011-10-06
JP2007523847A (ja) 2007-08-23
EP2540736A2 (en) 2013-01-02
JP5307169B2 (ja) 2013-10-02
CA2847486A1 (en) 2004-11-11
AU2003232253A1 (en) 2004-11-23
KR20130059462A (ko) 2013-06-05
JP5770781B2 (ja) 2015-08-26
US9518092B2 (en) 2016-12-13
IL227932B (en) 2019-01-31
EP1622931A1 (en) 2006-02-08
NO20131086A1 (no) 2005-11-25
BRPI0409928A8 (pt) 2019-09-10
KR101330238B1 (ko) 2013-11-15
WO2004096839A1 (en) 2004-11-11
US8895695B2 (en) 2014-11-25
AU2004234062B2 (en) 2010-07-15
IL227933B (en) 2019-01-31
CN1802385A (zh) 2006-07-12
BR122019016211B1 (pt) 2020-05-12
JP4846564B2 (ja) 2011-12-28
NO340835B1 (no) 2017-06-26
BRPI0409928B1 (pt) 2020-05-12
CA2847486C (en) 2016-03-15
AU2003232253A8 (en) 2004-11-23
KR101230453B1 (ko) 2013-02-06

Similar Documents

Publication Publication Date Title
BR122019016211B8 (pt) composto, composição farmacêutica, uso do composto e processo para a fabricação do mesmo
BR112021023814A2 (pt) Inibidores de proteases de cisteína e métodos de uso das mesmas
BR0017050A (pt) Oxazolidinonas suebstituìdas e seu emprego na área da coagulação do sangue
BR0316234A (pt) Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos
BR0207502A (pt) Compostos, enanciÈmeros, composição farmacêutica, uso de compostos, e, processo para a fabricação de compostos
ES2710126T3 (es) Extracto de saliva completa de sanguijuela
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
BR0108677A (pt) Novos compostos
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
BR112013031098A2 (pt) halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2
BRPI0408767B8 (pt) inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica
BRPI0409498A (pt) uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto
BR112014015630A2 (pt) fluorometil-5,6-di-hidro-4h-[1,3]oxazinas
BR112014010590A2 (pt) 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose
BRPI0815547B8 (pt) composição farmacêutica compreendendo depsipeptídeos cíclicos, e seus usos
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BR112022020315A2 (pt) Novos compostos anti-helmínticos
Shugars et al. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type 1
BRPI0520016A2 (pt) compostos, enanciÈmeros, composição farmacêutica, uso de compostos, processo para a fabricação de compostos, e, modificação dos processos
BR112022002156A2 (pt) Composição farmacêutica para tratamento da febre suína africana e seu uso
BR112023024433A2 (pt) Análogos, conjugados e métodos de uso de camptotecina
BR112015019568A2 (pt) Peptídeo isolado, composição compreendendo o mesmo e uso do mesmo
BR0306927A (pt) Compostos tricìclicos de 2-pirimidona úteis como inibidores de transcriptase reversa de hiv

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/04/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B22B Petition not considered [chapter 22.2 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 870210087251, DE 22/09/2021, EM VIRTUDE DO DISPOSTO NO ART. 219 , INCISO II DA LPI